Gene · 554
Papers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,581 to 1,600 of 2,697
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Complementary Hydrogen Bonding Modulates Electronic Properties and Controls Self-Assembly of Donor/Acceptor Semiconductors. | Chemistry | 2016 | 27739184 | PubTator, text mining | PubMed |
| Romantic Love vs. Drug Addiction May Inspire a New Treatment for Addiction. | Front Psychol | 2016 | 27713720 | PubTator, text mining | PubMed |
| Signaling through hepatocyte vasopressin receptor 1 protects mouse liver from ischemia-reperfusion injury. | Oncotarget | 2016 | 27713143 | PubTator, text mining | PubMed |
| The importance of total kidney volume in evaluating progression of polycystic kidney disease. | Nat Rev Nephrol | 2016 | 27694979 | PubTator, text mining | PubMed |
| Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial. | Am J Kidney Dis | 2016 | 27663039 | PubTator, text mining | PubMed |
| Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus. | PLoS One | 2016 | 27649563 | PubTator, text mining | PubMed |
| The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. | BMC Cardiovasc Disord | 2016 | 27624603 | PubTator, text mining | PubMed |
| Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist. | J Biol Chem | 2016 | 27601473 | PubTator, text mining | PubMed |
| Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass. | J Cardiothorac Vasc Anesth | 2016 | 27591907 | PubTator, text mining | PubMed |
| Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. | Cancer Manag Res | 2016 | 27578998 | PubTator, text mining | PubMed |
| [Analysis of AVPR2 gene mutation in a pedigree affected with congenital nephrogenic diabetes insipidus]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2016 | 27577218 | PubTator, text mining | PubMed |
| Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. | Lab Invest | 2016 | 27571215 | PubTator, text mining | PubMed |
| A novel AVPR2 gene mutation of X-linked congenital nephrogenic diabetes insipidus in an Asian pedigree. | J Int Med Res | 2016 | 27565746 | PubTator, text mining | PubMed |
| Core-Substituted Naphthalenediimides: LUMO Levels Revisited, in Comparison with Preylenediimides with Sulfur Redox Switches in the Core. | ChemistryOpen | 2016 | 27551658 | PubTator, text mining | PubMed |
| Three new species of western California springsnails previously confused with Pyrgulopsis stearnsiana (Caenogastropoda, Hydrobiidae). | Zookeys | 2016 | 27551184 | PubTator, text mining | PubMed |
| TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE. | Arch Dis Child | 2016 | 27540244 | PubTator, text mining | PubMed |
| Physiological insights into novel therapies for nephrogenic diabetes insipidus. | Am J Physiol Renal Physiol | 2016 | 27534996 | PubTator, text mining | PubMed |
| Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. | Nature | 2016 | 27525504 | PubTator, text mining | PubMed |
| Oxytocin and arginine vasopressin receptor evolution: implications for adaptive novelties in placental mammals. | Genet Mol Biol | 2016 | 27505307 | PubTator, text mining | PubMed |
| GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling. | Cell | 2016 | 27499021 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/554/papers?page=80